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Abstract
 
Integrin-mediated adhesion and B cell antigen receptor (BCR) signaling play a critical role in B
cell development and function, including antigen-specific B cell differentiation. Here we show
that the BCR controls integrin 
 
 
 
4
 
 
 
1 (VLA-4)-mediated adhesion of B cells to 
 
v
 
ascular cell
adhesion molecule-1 and fibronectin. Molecular dissection of the underlying signaling mecha-
nism by a combined biochemical, pharmacological, and genetic approach demonstrates that
this BCR-controlled integrin-mediated adhesion requires the (consecutive) activation of Lyn,
Syk, phosphatidylinositol 3-kinase, Bruton’s tyrosine kinase (Btk), phospholipase C (PLC)
 
 
 
2,
IP3R-mediated Ca
 
2
 
 
 
 release, and PKC. In contrast, activation of mitogen-activated protein
kinase kinase (MEK) or extracellular signal–regulated kinase (ERK) is not required, and simul-
taneous activation of MEK, ERK, and PKB is not sufficient either. Furthermore, Btk is also
involved in the control of integrin-mediated adhesion of preB cells. The control of integrin
 
 
 
4
 
 
 
1-mediated B cell adhesion by the BCR involves cytoskeletal reorganization and integrin
clustering. These results reveal a novel function for the BCR and Btk, i.e., regulation of inte-
grin 
 
 
 
4
 
 
 
1 activity, thereby providing new insights into the control of B cell development and
differentiation, as well as into the pathogenesis of the immunodeficiency disease X-linked
agammaglobulineamia (XLA).
Key words: lymphocyte adhesion • B-cell development • X-linked agammaglobulinaemia • 
germinal center • VCAM-1
 
Introduction
 
Integrin-mediated cell–cell and cell–matrix adhesion, as
well as migration, play an important role in a wide variety
of processes controlling B-lymphocyte development and
function. During early B cell development in the BM,
hematopoietic progenitor cells successively develop into
pro-, pre-, and immature B cells, which will emigrate into
the  bloodstream. This development occurs in defined
microenvironments and is controlled by integrin 
 
 
 
4
 
 
 
1-
mediated interactions with fibronectin (FN) in the ECM
and with vascular cell adhesion molecule (VCAM)-1 express-
ing BM stromal cells (1–4). Furthermore, integrins mediate
the transendothelial migration of mature B cells required
for their recirculation and homing (5–8), and play a key
role in antigen-specific B cell differentiation.
Antigen-specific B cell differentiation takes place within
germinal centers (GCs), specialized microenvironments in
the B cell area of secondary lymphoid organs (9–11). Here,
T cell-dependent humoral immune responses are initiated
by the activation of naive B cells in the T cell (paracortical)
area, which leads to their migration into B cell follicles
where they initiate the formation of GCs. In the GC, the B
cells undergo rapid clonal expansion and somatic hypermu-
tation of their immunoglobulin (Ig) genes. The mutated B
cells reencounter antigen, presented by follicular dendritic
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Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; Btk, Bruton’s
tyrosine kinase; CD, cytochalasin D; CP, Calpeptin; DG, diacylglycerol;
ERK, extracellular signal–regulated kinase; FDC, follicular dendritic cell;
FN, fibronectin; GC, germinal center; IP3, inositol-1,4,5-trisphosphate; JP,
jasplakinolide; MAPK, mitogen-activated protein kinase; MEK, MAPK
kinase; MFI, mean fluorescence intensity; PI3K, phosphatidylinositol
3-kinase;  PKC, protein kinase C; PLC, phospholipase C; PLL, poly-
 
l
 
-
lysine; VCAM, vascular cell adhesion molecule; Xid, X-linked immunode-
ficiency; XLA, X-linked agammaglobulinaemia.T
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cells (FDCs), and undergo affinity maturation: B cells
expressing high affinity B cell antigen receptor (BCR)
mutants will be rescued from apoptosis by their interac-
tion with the FDC (11, 12), expand, undergo Ig-isotype
switching, and mature into memory B cells or plasma cells.
The interaction with FDCs is mediated by the integrins
 
 
 
4
 
 
 
1 and 
 
 
 
L
 
 
 
2 (LFA-1) expressed on the GC B cell,
which engage VCAM-1 and ICAM-1 on the FDC, respec-
tively (13–15). Interestingly, apart from establishing physical
contact, outside-in signaling by 
 
 
 
4
 
 
 
1 and LFA-1 has been
shown to suppress apoptosis of GC B cells (16, 17). Hence,
integrin-mediated interactions of GC B cells with FDCs
play a key role in antigen-specific B cell differentiation (11).
This notion is further supported by the observations that the
T cell-dependent humoral immune response is impaired in
mice lacking expression of VCAM-1 on FDCs (2) or of in-
tegrin 
 
 
 
1 in the hematopoietic system (18).
Despite the important role of integrins in B cell develop-
ment and antigen-specific B cell differentiation, the stimuli
and underlying signal transduction mechanisms that control
integrin activity of B cells are as yet poorly defined. Given
the critical role of the (pre)BCR in B cell development and
differentiation (19–22), we asked whether the BCR may
control integrin-mediated adhesion of B cells and, if so,
what is the signal transduction mechanism involved. BCR
signal transduction involves a wide variety of signaling mol-
ecules (20, 23, 24), some of which, e.g., phosphatidylinositol
3-kinase (PI3K), phospholipase C (PLC), protein kinase C
(PKC), extracellular signal–regulated kinase
 
 (
 
ERK) and sev-
eral members of the Ras family, have been implicated in the
control of integrin activity by other receptors (25, 26).
Here, we demonstrate that stimulation of the BCR induces
integrin 
 
 
 
4
 
 
 
1-mediated adhesion of B cells to VCAM-1
and FN. Furthermore, our data reveal a critical role for the
consecutive activation of Lyn, Syk, PI3K, Bruton’s tyrosine
kinase (Btk), PLC
 
 
 
2, IP3R-mediated Ca
 
2
 
 
 
 release, and
PKC in the BCR-controlled inside-out signaling mecha-
nism underlying 
 
 
 
4
 
 
 
1 activation, which involves cytoskele-
tal reorganization and integrin clustering. These results ex-
plain how the concerted action of both BCR signaling and
integrin activation, as well as outside-in signaling, is con-
trolled and contributes to antigen-specific B cell differentia-
tion. In addition, our study reveals a novel function for Btk,
which suggests that a loss of control of integrin activity con-
tributes to the developmental and functional B cell defects
observed in the immunodeficiency disease X-linked agam-
maglobulinemia (XLA).
 
Materials and Methods
 
Materials.
 
The following reagents were used in this study: the
phosphorylation state-specific antibodies phospho-p44/42 MAP
kinase [T202/Y204] against ERK1 and 2 and phospho-Akt
[Ser473] against PKB/Akt (New England Biolabs); anti-ERK2
(C-14) and anti-Akt1/2 (H-136; Santa Cruz Biotechnology); the
mouse monoclonal IgG1 antibodies HP2/1 against integrin sub-
unit 
 
 
 
4 (Immunotech); Act-1 against integrin subunit 
 
 
 
7 (kindly
provided by Dr. A. Lazarovits); TS2/16 against integrin subunit
 
 
 
1 (kindly provided by Dr. F. Sanchez-Madrid); TS1/22 against
integrin subunit 
 
 
 
L
 
 (ATCC); CSAT IgG2b against the chicken
integrin subunit 
 
 
 
1 (DSHB, University of Iowa); and the rat
monoclonal antibodies OXM718-FITC and PS/2-biotin against
mouse integrin 
 
 
 
4 and 
 
 
 
1, respectively (Cymbus Biotechnology).
Mouse anti-T7-tag (Novagen); anti-CD45R(B220) and anti-
mouse IgM microbeads (Miltenyi Biotec); mouse anti-human
IgM (MH15; kindly provided by the Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service, Amsterdam,
the Netherlands). Streptavidin-PE, Streptavidin-FITC, goat-anti
mouse-Biotin, and (Fab)
 
2
 
-fragments of goat anti-human IgM
(DAKO); goat anti-mouse IgM and goat anti-mouse-PE (Southern
Biotechnology Associates), (Fab)
 
2
 
-fragments of goat anti-mouse
IgM and goat anti-human Fc-FITC (Jackson Immunoresearch
Laboratories), goat anti-chicken IgM (Bethyl Laboratories), and
rabbit anti-goat-Biotin (Vector). The pharmacological inhibitors
PD-98059, LY-294002, Wortmannin, U-73122, Chelerythrine,
cytochalasin D, Jasplakinolide, and Calpeptin (Biomol). Recom-
binant human sVCAM-1 (R&D Systems), human plasma Fi-
bronectin, BSA (fraction V) and poly-
 
l
 
-Lysine (PLL) (Sigma-
Aldrich).
 
Cell Lines and Culture.
 
The Burkitt’s lymphoma cell line Na-
malwa clone V3M (27) and the human preB cell line Nalm6 (28)
were cultured as described. The chicken bursal lymphoma B cell
line DT40 and DT40 cells deficient for both Lyn and Syk (29),
Btk (29), PLC
 
 
 
2 (30), and for all three types of IP3R (31), ob-
tained from Riken Cell Bank (Tsukuba Science City, Japan) with
permission from Dr. T. Kurosaki (Kansai Medical University,
Moriguchi, Japan), were cultured at 39.5
 
 
 
C as described (32). All
DT40 cells, i.e., WT, gene-deficient and reconstituted (see be-
low), showed similar expression of surface IgM and integrin 
 
 
 
1, as
determined by FACS analysis, using goat anti-chicken IgM (10
 
 
 
g/ml) and rabbit anti-goat-Biotin/Streptavidin-PE, or CSAT (3
 
 
 
g/ml) and goat anti-mouse-PE, respectively, analyzed with a
FACSCalibur
 
TM
 
 (Beckton Dickinson) using CELLQuest software.
 
Isolation of Primary Tonsillar and Splenic B Cells.
 
Human ton-
sillar B cells were isolated essentially as previously described (16).
Typically, the obtained cell population contains 
 
 
 
97% B cells as
determined by FACS analysis. Isolated B cells were maintained in
RPMI containing 10% FCS and were used immediately or after
overnight storage at 4
 
 
 
C.
Mouse splenic B cells from C57BL/6 mice, which were bred
and maintained at the animal care facility of the Academic Medi-
cal Center, were obtained using the MACS system (Miltenyi
Biotec) by positive selection with anti-CD45R (B220) micro-
beads, essentially according to manufacturer’s instruction.
 
Mice and BM Cultures.
 
Btk
 
 
 
/LacZ mice were crossed onto a
C57BL/6 background for over 6 generations, and Btk genotyped
as described (33). 3–83 
 
  
 
 Ig transgenic mice which bear 3–83 Ig
heavy and 
 
 
 
-light chain transgenes (anti-H-2Kkb) on a B10.D2
background (34), were crossed with WT or Btk-deficient mice.
These mice were bred and maintained at the animal care facility
of the Erasmus MC (Rotterdam, the Netherlands).
To obtain mouse preB cells or B cells, IL-7-driven primary BM
cultures of WT and Btk-deficient mice, or of 3–83 transgenic WT
and Btk-deficient mice, respectively, were performed essentially as
described (35, 36). In brief, BM cells were erythrocyte depleted
and cultured at 10
 
7
 
 cells/4 ml/well in 6-well plates in IMDM sup-
plemented with 10% FCS and 100 U/ml murine IL-7 (R&D) for
5 d. Naive B cells from IL-7-driven BM cultures of 3–83 
 
  
 
 Ig
transgenic WT and Btk-deficient mice were used since mature B
cells from Btk-deficient mice have an aberrant immature IgM
 
high
 
phenotype. The IL-7 driven BM cultures of the nontransgenicT
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WT or Btk-deficient mice typically resulted in 
 
 
 
98% B220
 
 
 
 cells
and 
 
 
 
80% and 95% preB cells (B220
 
 
 
/IgM
 
 
 
), respectively. Cul-
tures from 3–83 transgenic mice contained 
 
 
 
95% B220
 
 
 
/IgM
 
 
 
 B
cells. Expression levels of integrin 
 
 
 
4 and 
 
 
 
1 on mice preB cells
were determined by FACS analysis using OXM718-FITC (1:20)
and PS/2-biotin (1:80) antibodies, respectively.
 
Generation of Reconstituted DT40 Cells.
 
The reconstitution of
the Btk- or PLC
 
 
 
2-deficient DT40 cell lines was performed by
electroporation, using pApuro expression vectors containing the
T7-tagged cDNAs for human Btk (29) and rat PLC
 
 
 
2 (30),
which were provided by Dr. T. Kurosaki (Kansai Medical Uni-
versity, Moriguchi, Japan). Briefly, 25 
 
 
 
g linearized plasmid
DNA (pApuro-T7-Btk or T7-PLC
 
 
 
2) was added to 10
 
7
 
 cells in
0.5 ml culture medium in a 0.4 cm electrode gap Gene Pulser
Cuvette (BioRad) and electroporated using a Gene Pulser Appa-
ratus with Capacitance Extender (BioRad) at 250 V, 960 
 
 
 
F. Af-
ter 24 h recovery at 39.5
 
 
 
C in DT40 medium, cells were selected
in DT40 medium containing 0.5 
 
 
 
g/ml Puromycin (Sigma).
Puromycin-resistant clones were screened for expression of the
transgene by immunoblotting with anti-T7. At least three clones
of each reconstituted stable cell line were tested and found to be
functionally restored in BCR-induced adhesion.
 
Immunoblotting.
 
After stimulation of 10
 
7
 
 cells /ml RPMI with
10 
 
 
 
g/ml anti-IgM antibody, cells were directly lysed in SDS-
PAGE sample buffer. 2 
 
 
 
 10
 
5
 
 cells were applied on a 10% SDS-
PAGE gel and blotted with anti-phospho-mitogen-activated pro-
tein kinase (MAPK)1/2 and anti-phospho-PKB, followed by
HRP-conjugated goat anti-rabbit and developed by enhanced
chemiluminescence (Amersham Pharmacia). To confirm equal
expression (WT versus deficient DT40 cells) and loading, the
blots were stripped or occasionally blots were generated in a par-
allel fashion, and incubated with the antibodies anti-ERK2 and
anti-PKB.
 
Cell Adhesion Assay.
 
Adhesion assays were done in triplicate
on round-bottom 96-well plates (Costar) coated overnight at 4
 
 
 
C
with PBS containing, unless otherwise indicated, 1 
 
 
 
g/ml
sVCAM-1, 10 
 
 
 
g/ml Fibronectin, 4% BSA, or for 15 min at
37
 
 
 
C with 1 mg/ml poly-
 
l
 
-lysine (PLL), and blocked for 2 h at
37
 
 
 
C with 4% BSA in RPMI 1640. Cells were pretreated with
the pharmacological inhibitors at 37
 
 
 
C or anti-integrin antibodies
TS1/22 (1:1000), Act-1 (1:100), TS2/16 (1:5), and HP2/1
(1:250) at 4
 
 
 
C for 30 min in RPMI with 1% BSA. Subsequently,
cells were stimulated with either 10 
 
 
 
g/ml mouse anti-human
IgM MH15, goat anti-chicken IgM, (Fab)
 
2
 
 fragments of anti-
human or anti-mouse IgM, anti-mouse IgM microbeads (1:300) or
50 ng/ml PMA, and 1.5 
 
 
 
 10
 
5
 
 Namalwa or DT40 cells, or 3 
 
 
 
10
 
5
 
 primary B cells, were plated in 100 
 
 
 
l/well and incubated at
37
 
 
 
C (39.5
 
 
 
C for DT40) for 30 min, unless otherwise indicated.
After extensive washing of the plate with RPMI containing 1%
BSA to remove nonadhering cells, the adherent cells were fixed
for 10 min with 10% glutaraldehyde in PBS and stained for 45
min with 0.5% crystal violet in 20% methanol. After extensive
washing with water, the dye was eluted in methanol and absor-
bance was measured after 5 to 40 min at 570 nm on a spectro-
photometer (Microplate Reader 450, Biorad). Background ab-
sorbance (no cells added) was subtracted. Absorbance due to
nonspecific adhesion, as determined in wells coated with 4%
BSA, was always less than 10% of the absorbance of anti-IgM-
stimulated cells. Maximal (100%) adhesion was determined by ap-
plying the PMA-stimulated cells to wells coated with the posi-
tively charged PLL, resulting in nonspecific adhesion of all cells,
without washing the wells before fixation (see also Fig. 1, A-D).
Unless otherwise indicated, adhesion of the nonpretreated anti-
 
IgM-stimulated cells was normalized to 100% and the bars repre-
sent the means 
 
 
 
SD of a triplicate experiment representative of at
least three independent experiments.
 
Soluble VCAM-1 Binding Assay.
 
DT40 cells were incubated
with or without 10 
 
 
 
g/ml goat anti-chicken IgM in RPMI 
 
 
 
1% BSA for 10 min at 39.5
 
 
 
C. Subsequently 5   104 cells were
incubated in a 96-well V-shaped bottom plate without or with 2
or 10  g/ml soluble VCAM-1-Fc (kindly provided by Y. van
Kooyk) in the absence or presence of 3 mM MnCl2 in a final vol-
ume of 25  l for 30 min at 4 C (similar results were obtained
when anti-IgM or MnCl2 and VCAM-1-Fc were added simulta-
neously and cells were incubated for 30 min at 39.5 C). After
washing the cells twice, the cells were incubated with goat anti-
human Fc-FITC (1:200) in RPMI   1% BSA for 30 min at 4 C,
washed twice, and analyzed by FACS. Mean fluorescence inten-
sity (MFI) values are depicted after subtraction of the MFI values
obtained in the absence of soluble VCAM-1-Fc.
Analysis of Integrin  4 1 Clustering by Confocal Microscopy.
DT40 cells (1.5   105) were incubated with or without 10  g/ml
goat anti-chicken IgM in RPMI for different time periods at
39.5 C. Subsequently, cells were fixed with 4% paraformaldehyde
in PBS for 15 min at RT, incubated with 7.5  g/ml CSAT for
30 min at 4 C, washed, incubated with biotinylated goat-anti
mouse (1:400) for 30 min at 4 C, washed, incubated with
Streptavidin-FITC (1:200) for 15 min at 4 C, and washed again.
Finally, the cell suspension was spotted onto 0.1% PLL-coated
slides, and after 5 min the slides were rinsed and cells were
mounted in Vectashield for confocal laser scanning microscopy,
using a Leica TCS SP2 with a krypton/argon laser at 488 nm and
a 63x lens. To evaluate integrin clustering, horizontal 0.6  m op-
tical serial sections were taken throughout the cell. Clustering was
inspected at midheight optical sections and by whole cell projec-
tions along the z-axis using maximum fluorescence values.
Statistical Analysis. The unpaired two-tailed Student’s t test
was used to determine the significance of differences between
means. All relevant comparisons (e.g., control versus inhibitors or WT
versus deficient DT40) were significantly different (P   0.01).
Results
BCR Activation Induces Integrin  4 1-mediated B Cell Ad-
hesion to VCAM-1 and FN. To investigate whether the
BCR is able to control B cell adhesion, freshly isolated
human tonsillar and murine splenic B cells were stimu-
lated with anti-IgM antibody to ligate and activate the
BCR, or with the phorbol ester PMA to activate PKC,
and plated on a surface coated with either VCAM-1 or
FN. As shown in Fig. 1, A and B, BCR activation, as well
as PMA treatment, resulted in a strong stimulation of ad-
hesion to both VCAM-1 and FN. Anti-IgM stimulation,
as well as PMA-treatment of the human B cell line Nama-
lwa, which resembles GC B cells, also resulted in strongly
enhanced adhesion to both VCAM-1 and FN (Fig. 1 C).
Similar results were obtained using chicken DT40 B cells
(Fig. 1 D).
As shown in Fig. 1 E, antibody HP2/1, known to block
 4 1 function, specifically and completely blocked both
basal as well as BCR-induced adhesion of Namalwa cells to
VCAM-1, whereas no effect was observed with either an
isotype control IgG1, or the specific antibodies TS1/22,
blocking LFA-1, or Act-1, blocking integrin  4 7. On theT
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other hand, antibody TS2/16, known to activate integrin
 4 1, strongly promoted adhesion to VCAM-1. Further-
more, the antibody CSAT, directed against the chicken in-
tegrin  1 subunit, blocked the BCR-controlled adhesion
of DT40 cells to VCAM-1 (Fig. 1 F). Taken together, our
data demonstrate that stimulation of the BCR of either pri-
mary B cells or B cell lines results in their enhanced adhe-
sion to VCAM-1, which is mediated by integrin  4 1.
BCR-controlled Adhesion Requires Activation of Lyn, Syk,
and PI3K, but Not MAPK Kinase or ERK. Given the
proximal and prominent role in BCR signaling for Lyn, a
Src-family tyrosine kinase, and Syk, a member of the
ZAP70/Syk family of tyrosine kinases, we investigated
their possible role in the regulation of integrin-mediated
adhesion by the BCR. As shown in Fig. 2 A, in Lyn/Syk
double-deficient DT40 cells the BCR-induced adhesion to
VCAM-1 was completely abolished.
As shown in Fig. 2, B and C, BCR stimulation of DT40
and Namalwa cells results in a strong activation of PKB/
Akt-1 and the MAP kinase ERK2/MAPK1 and, in Na-
malwa cells, also of ERK1. In agreement with previous
studies (37–41), and confirming the prominent role of Lyn
and Syk in BCR signaling, the BCR-induced activation of
PKB and ERK2 was completely abolished in the Lyn/Syk-
deficient cells (Fig. 2 B), whereas their activation by PMA
was not affected (data not depicted). Furthermore, the acti-
vation of ERK1 and 2 is completely abolished by pretreat-
ment of the cells with the MAPK kinase (MEK) inhibitor
Figure 1. BCR activation induces integrin  4 1-mediated
B cell adhesion to VCAM-1 and FN. (A) Primary tonsillar
B cells were not stimulated (C) or stimulated with (Fab)2-
fragments of anti-IgM (a-IgM) or PMA and plated for 20
min on a surface coated with either VCAM-1 or FN, as
indicated. (B) Mouse splenic B cells were not stimulated
(C) or stimulated with (Fab)2-fragments of anti-IgM (a-IgM),
or PMA and plated on a surface coated with 0.3  g/ml
VCAM-1. (C) Namalwa cells were not stimulated (C) or
stimulated with anti-IgM (a-IgM) or PMA and plated on a
surface coated with either VCAM-1 or FN, as indicated.
(D) DT40 cells were not stimulated (C) or stimulated with
anti-IgM (a-IgM) or PMA and plated on a surface coated
with VCAM-1. (E) Namalwa cells were preincubated for
1 h at 4 C with medium alone (none), 10  g/ml of an IgG1
isotype control (IgG1), or antibody TS1/22 blocking LFA-1
(TS1/22), Act-1 blocking  4 7 (Act-1), HP2/1 blocking
 4 1 (HP2/1), or antibody TS2/16 activating integrin
 4 1 (TS2/16). Subsequently, cells were not stimulated
(C) or stimulated with anti-IgM (a-IgM), as indicated, and
plated on a surface coated with VCAM-1. (F) DT40 cells
were preincubated for 1 h at 4 C with medium alone
(none), or 10  g/ml of an IgG2b isotype control (IgG2b)
or antibody CSAT against integrin subunit  1 (CSAT).
Subsequently, cells were stimulated with anti-IgM and
plated on a surface coated with VCAM-1. (A-D) The ad-
hesion is presented as absolute adhesion, with input being
determined by adhesion of all cells to PLL (  100% adhe-
sion). (E and F) The adhesion was normalized to 100% for
the anti-IgM-stimulated cells.T
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PD-98059 (PD), but not in DT40, and only partially in
Namalwa, by treatment with the PI3K inhibitors LY-
294002 (LY) or Wortmannin (WM) (Fig. 2 C). By con-
trast, PKB activation was completely abrogated by pretreat-
ment with the PI3K inhibitors LY and WM, but was not
affected by the MEK inhibitor PD (Fig. 2 C). Thus, BCR
stimulation results in activation of PI3K, which is required
for the activation of PKB and, in Namalwa, is also partially
involved in the activation of ERK.
PI3K, MEK, and ERK have previously been implicated
in the regulation of integrin activity by other stimuli (25).
As shown in Fig. 2 D, the BCR-induced integrin-medi-
ated adhesion to VCAM-1 of both Namalwa and DT40
cells was completely abolished upon treatment of the cells
with the PI3K inhibitors LY or WM, whereas treatment
with the MEK inhibitor PD had no effect. Taken together,
these data demonstrate that Lyn- and Syk-dependent acti-
vation of PI3K is required for BCR-induced  4 1 activa-
tion, whereas activation of MEK or ERK is not involved.
Btk Is Required for BCR-controlled Adhesion. PI3K acti-
vation results in the formation of phosphatidylinositol 3,4,5-
trisphosphate (PIP3). PIP3 mediates the plasma membrane
translocation and activation of several signaling molecules,
including the cytoplasmic tyrosine kinase Btk, the serine/
threonine kinase PKB, or the exchange factor Vav, as a
consequence of the interaction of their PH domains with
PIP3. Interestingly, using Btk-deficient DT40 cells, we
observed a complete loss of BCR-, but not PMA-, in-
duced adhesion to VCAM-1 (Fig. 3 A). This defect is not
due to clonal variation since it could be completely re-
stored by stable transfection of an expression construct en-
coding Btk (Fig. 3 A). In agreement with previous data,
we observed that, whereas ERK2 activation was reduced
in the Btk-deficient DT40 cells (40), PKB activation re-
mained unaffected (37, 41; however see 39) (Fig. 3 B).
Thus, whereas (PI3K-mediated) activation of PKB is not
sufficient, Btk is required for activation of integrin  4 1
by the BCR.
These observations are particularly interesting since Btk-
deficiency causes the B cell immunodeficiency disease XLA
in humans and X-linked immunodeficiency (Xid) in mice.
Therefore, we further studied the role of Btk in BCR-
induced adhesion using B cells derived from Btk-deficient
mice. As shown in Fig. 3 C, Btk-deficiency did not affect
BCR-controlled integrin-mediated adhesion of mouse B
cells. This difference with the chicken DT40 cells may be
due to species-specific functional redundancy of Btk for
other tec-family kinases in mouse B cells (see Discussion).
Pre-B cell differentiation, which is controlled by the
presumably constitutively active ligand-independent pre-
Figure 2. BCR-controlled ad-
hesion is dependent on Lyn and
Syk and requires activation of
PI3K, but not of MEK or ERK.
(A) WT or Lyn/Syk double-
deficient DT40 cells (Lyn /Syk )
were not stimulated (C) or stimu-
lated with anti-IgM (a-IgM) and
plated on a surface coated with
VCAM-1. (B) Activation of PKB
and ERK in WT or Lyn/Syk
double-deficient DT40 cells
(Lyn /Syk ) after stimulation
with anti-IgM for the indicated
period of time (min). The immu-
noblots are probed with anti-
phospho-PKB (P-PKB) and anti-
phospho-MAPK (P-ERK) and
reprobed with anti-ERK2 and
anti-PKB, as indicated. (C) Acti-
vation of PKB and ERK in Na-
malwa  cells (left) or DT40 cells
(right) which were pretreated with
20  M LY294002 (LY), 100 nM
Wortmannin (WM), 50  M
PD98059 (PD), or left untreated
( ) for 30 min, and stimulated with
anti-IgM (a-IgM) or not (C) for 5
min, as indicated. The blots are
probed as in B. (D) Namalwa cells
(left) or DT40 cells (right) were
pretreated with 50  M LY294002
(LY), 100 nM Wortmannin
(WM), 50  M PD98059 (PD), or
left untreated for 30 min, and not
stimulated (C) or stimulated with
anti-IgM (a-IgM) and plated on a
surface coated with VCAM-1.T
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BCR (19, 21, 22, 42), is impaired in Btk-deficient mice
(33, 43) and almost completely arrested in XLA patients
(44, 45). Interestingly, using mouse preB cells and the hu-
man preB cell line Nalm6, in which Btk is constitutively
phosphorylated (46, 47), we observed high basal integrin-
mediated adhesion which, in contrast to DT40 or Na-
malwa cells, could not be further enhanced by PMA (Fig.
3, D and E). Noteworthy, the PI3K inhibitor Wortmannin
reduced the high basal adhesion of the Nalm6 cells (on 0.125
 g/ml VCAM-1; data not depicted). Moreover, preB cells
derived from Btk-deficient mice showed an  50% lower
basal adhesion in comparison to WT preB cells, which
could be enhanced by PMA up to the level of adhesion of
the WT preB cells (Fig. 3 E). The WT and Btk-deficient
preB cells display similar expression levels of integrin  4
and   1, as determined by FACS analysis (data not de-
picted). Since the preBCR signals in a presumably consti-
tutively active ligand-independent fashion involving Btk
(42, 46, 48, 49), these results suggest that Btk mediates
integrin activation by the preBCR. In conclusion, our
data reveal a critical regulatory function for Btk in the
(pre)BCR-controlled integrin-mediated adhesion.
BCR-controlled Adhesion Requires PLC 2 Activation,
IP3R-mediated Ca2  Release, and PKC Activation. Given
the intriguing critical role of Btk in BCR-induced integrin
activation, we wished to further extend and strengthen our
observations by exploring which signaling molecules may
control this process downstream from Btk. A major candi-
date is PLC 2, since it has been implicated in BCR signal-
ing, and has been identified as a substrate for both Btk and
Syk (29). Indeed, as shown in Fig. 4 A, treatment of Na-
malwa or DT40 cells with the PLC inhibitor U73122
abolished BCR-induced VCAM-1 adhesion. Noteworthy,
U73122 also strongly reduced the high basal adhesion of
the Nalm6 cells (on 0.125  g/ml VCAM-1) (data not de-
picted). Moreover, PLC 2-deficient DT40 cells showed a
complete loss of BCR-, but not PMA-, induced VCAM-1
adhesion (Fig. 4 B), which could be completely restored by
gene complementation with a PLC 2 expression construct
(Fig.4 B).
PLC activation results in the hydrolysis of phosphatidyl-
inositol-4,5-bisphosphate (PIP2) into inositol-1,4,5-tris-
phosphate (IP3) and diacylglycerol (DG). IP3 binds to IP3Rs
on the endoplasmic reticulum resulting in the release of
Ca2 , whereas DG activates PKC. Using IP3R-triple-defi-
cient DT40 cells, in which the genes encoding all three
types of IP3Rs expressed in these cells have been in-
activated resulting in a loss of BCR-mediated Ca2  release
(31), we observed a complete loss of BCR-induced
VCAM-1 adhesion (Fig. 4 C). Furthermore, in agreement
with previous reports (32, 37, 39, 41), PKB activation does
not require any PLC 2- or IP3R-mediated signals, whereas
ERK activation involves DG-dependent activation of PKC
but not IP3R-mediated Ca2 -release (Fig. 4 D). Thus, the
IP3R-deficient B cells reveal that simultaneous activation
of both PKB and ERK is not sufficient for integrin  4 1
activation (Fig. 4, C and D). Finally, treatment of Namalwa
or DT40 cells with the PKC inhibitor Chelerythrine
Figure 3. Btk is required for
BCR-controlled adhesion. (A)
WT, Btk-deficient (Btk ), or
Btk-deficient DT40 cells recon-
stituted with Btk (Btk ) were
not stimulated (C) or stimulated
with anti-IgM (a-IgM) or PMA
and plated on a surface coated
with VCAM-1. The inset shows
expression of Btk in the Btk-
reconstituted DT40 cell-line as
detected by immunoblotting
with anti-T7. (B) Activation of
PKB and ERK in WT or Btk-
deficient (Btk ) DT40 cells after
stimulation with anti-IgM for
the indicated period of time
(min). The blots are probed as in
Fig. 2 B. (C) B cells from WT or
Btk-deficient (Btk ) mice were
not stimulated (C) or stimulated
with anti-IgM (a-IgM) or PMA
and plated for 15 min on a sur-
face coated with 0.3  g/ml
VCAM-1. The experiment shown
is representative for two indepen-
dent  experiments. (D) Nalm6
(circles), DT40 (squares), or Namalwa (triangles) cells were not stimulated (open symbols) or stimulated with PMA (closed symbols) and plated for 20
min on a surface coated with different concentrations of VCAM-1. The adhesion was normalized to 100% for the PMA-stimulated cells plated on 1  g/ml
VCAM-1. The experiment shown is representative for two independent experiments. (E) Pre-B cells from WT or Btk-deficient (Btk ) mice were not
stimulated (C) or stimulated with PMA and plated for 15 min on a surface coated with 0.3  g/ml VCAM-1. The adhesion was normalized to 100% for
the unstimulated WT preB cells. The bars represent the means  SD of 2 WT and 2 Btk-deficient mice, each assayed in triplicate. In a total of three
independent experiments (6 WT and 6 Btk-deficient mice), the basal adhesion of the Btk-deficient mice was 54%   10% in comparison to WT preB cells.T
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abolished PMA- (data not depicted) and BCR-induced
VCAM-1 adhesion (Fig. 4 E), whereas treatment with the
Ca2 -ionophore Ionomycin did not result in enhanced in-
tegrin-mediated adhesion (data not depicted). Combined,
these data indicate that activation of PLC 2 and subse-
quently the concomitant IP3R-mediated release of calcium
and DG-mediated activation of PKC are required for
BCR-controlled integrin  4 1-mediated adhesion.
BCR-controlled Integrin  4 1-mediated Adhesion Involves
Cytoskeletal Reorganization and Integrin Clustering. Integrin
activation can be accomplished by a conformational change
resulting in enhanced ligand affinity, by an increase in lateral
mobility and clustering resulting in enhanced avidity, or
both (25, 26). As shown in Fig. 5 A, whereas MnCl2 treat-
ment resulted in enhanced binding of soluble VCAM-1 to
DT40 cells, no change of  4 1 affinity for VCAM-1 was
observed after stimulation with anti-IgM. In contrast, con-
focal microscopy analysis revealed enhanced  4 1 cluster-
ing after anti-IgM stimulation of DT40 cells. Stimulation
with anti-IgM for 15 min results in the formation of many
small clusters, whereas after 30 min rather large clusters of
 4 1 are observed (Fig. 5 B). PMA stimulation results in
the formation of larger and more diffuse  4 1 clusters in
WT and Btk-deficient DT40 cells (Fig. 5 B). In Btk-defi-
cient DT40 cells, however, consistent with their disability
to adhere to VCAM-1 upon BCR activation (Fig. 3), no
anti-IgM-induced  4 1 clustering is observed (Fig. 5 B).
The actin cytoskeleton has been implicated in the con-
trol of clustering of integrins, including of LFA-1 and
 4 1, and in integrin-mediated adhesion (26, 50–54). To
investigate whether (re)organization of the actin cytoskele-
ton contributes to the BCR-induced  4 1-mediated ad-
hesion, and to provide further support for the role of  4 1
clustering in this process, we examined the effect of Cyto-
chalasin D (CD), which prevents actin filament polymer-
ization and organization, and Jasplakinolide (JP), which
prevents actin depolymerization and stabilizes preexisting
actin filaments. Since the Ca2 -dependent protease Calpain
has previously been implicated in TCR-, chemokine-, and
PMA-induced LFA-1 clustering and LFA-1-mediated T
cell adhesion (53, 55), and given the observed critical role
of IP3R-mediated Ca2 -release in BCR-controlled  4 1
activation (Fig. 4 C), we also studied the effect of an inhib-
itor of Calpain, Calpeptin (CP). As shown in Fig. 5 C, pre-
treatment of DT40 and Namalwa cells with CD, JP, or CP
completely abolished the BCR-induced  4 1-mediated
adhesion to VCAM-1. Taken together, these data indicate
that the control of integrin  4 1-mediated B cell adhesion
by the BCR involves cytoskeletal (re)organization and
stimulation of integrin avidity.
Discussion
The Inside-out Signaling Mechanism Underlying BCR-con-
trolled Integrin  4 1 Activation.  In this study we demon-
strate that stimulation of the BCR results in inside-out acti-
vation of integrin  4 1 and consequently in strongly
enhanced adhesion of B cells to FN and VCAM-1 (Fig. 1).
Using a combined biochemical, pharmacological, and ge-
netic approach, we also show that the tyrosine kinases Lyn
and Syk, as well as PI3K, are required for BCR-controlled
 4 1-mediated adhesion (Fig. 2). By contrast, activation of
Figure 4. BCR-controlled
adhesion requires activation of
PLC 2, IP3R-mediated Ca2 
release, and PKC. (A) Namalwa
cells (left) or DT40 cells (right)
were pretreated with 1 or 2.5
 M U73122 (U), respectively,
or left untreated for 30 min, and
subsequently not stimulated (C) or
stimulated with anti-IgM (a-IgM)
and plated on a surface coated
with VCAM-1. (B) WT,
PLC 2-deficient (PLC 2 ), or
PLC 2-deficient DT40 cells
reconstituted with PLC 2
(PLC 2 ) were not stimulated
(C) or stimulated with anti-IgM
(a-IgM) or PMA and plated on a
surface coated with VCAM-1.
The inset shows expression of
PLC 2 in the PLC 2-reconsti-
tuted DT40 cell-line as detected
by immunoblotting with anti-T7.
(C) WT or IP3R-deficient
DT40 cells (IP3R ) were not
stimulated (C) or stimulated with
anti-IgM (a-IgM) and plated on
a surface coated with VCAM-1.
(D) Activation of PKB and ERK in WT, PLC 2(PLC 2 )-, or IP3R(IP3R )-deficient DT40 cells after stimulation with anti-IgM for the indicated period of
time (min). The blots are probed as in Fig. 2 B. (E) Namalwa cells (left) or DT40 cells (right) were pretreated with 5 or 10  M Chelerythrine (CE), respectively,
or left untreated for 30 min, and subsequently not stimulated (C) or stimulated with anti-IgM (a-IgM) and plated on a surface coated with VCAM-1.T
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MEK or the MAP kinases ERK1 or 2 is not involved (Fig.
2 D). In concordance with the observed critical role of
Lyn, Syk, and PI3K in  4 1 activation, activation of PI3K
by the BCR can be mediated by Lyn (56, 57), and, via the
adaptor protein BCAP, by Syk (24, 38, 39). The use of
Btk-, PLC 2-, and IP3R-deficient B cells revealed that
PI3K-controlled activation of PKB, either alone or in
combination with ERK2, is not sufficient for  4 1 activa-
tion (Figs. 3 and 4). Interestingly, we found that the PI3K-
controlled tyrosine kinase Btk is a critical mediator of
BCR-induced adhesion (Fig. 3). Btk activation requires its
translocation to the plasma membrane by the interaction of
its PH domain with the PI3K product PIP3, and phosphor-
ylation of Y551 in the kinase domain activation loop (58).
Indeed, reflecting their role in PI3K activation or Y551
phosphorylation, BCR-controlled Btk activation is medi-
ated by Lyn and Syk (23, 24). We also found that the Btk
substrate PLC 2 mediates the BCR-controlled adhesion
(Fig. 4, A and B). PLC 2 activation by the BCR requires
phosphorylation of the adaptor BLNK by Syk, thus creat-
ing docking sites for the SH2 domains of Btk and PLC 2.
This brings PLC 2 into close proximity of Btk, resulting in
its phosphorylation and activation by Btk (24). The appar-
ent bifurcation of the signaling cascade underlying  4 1
activation downstream of PLC 2, i.e., concomitant IP3-
mediated Ca2  release and DG-mediated activation of
PKC (Fig. 4, C and E), either indicates the involvement of
a Ca2 -dependent DG-activated PKC isotype (i.e., PKC  
or  ), or the requirement for PKC activation and Ca2  re-
lease in a parallel fashion. Taken together, we have identi-
fied a (linear) cascade of essential signaling components
underlying BCR-controlled  4 1 activation, i.e., the
(consecutive) activation of Lyn, Syk, PI3K, Btk, PLC 2,
IP3R-mediated Ca2  release and PKC (Fig. 6), and al-
though any alternative or branching pathways may also
play a role, activation of those pathways alone will not be
sufficient for  4 1 activation by the BCR.
 4 1-mediated adhesion can be controlled by integrin
clustering (avidity) (50, 51, 54), or by active regulation of
 4 1 affinity (59, 60). Our data revealed that the stimula-
tion of the BCR results in enhanced  4 1 avidity, whereas
no change in affinity was observed (Fig. 5). The role for
 4 1 avidity regulation in the control of adhesion is fur-
ther supported by our observation that BCR-induced
 4 1-mediated adhesion is controlled by Ca2 -release,
activation of Calpain and (re)organization of the actin
cytoskeleton (Figs. 4 and 5), since these processes have
previously been implicated in clustering of integrins, in
particular of LFA-1, underlying TCR- and chemokine-
induced LFA-1-mediated adhesion (26, 51–55). In addition,
recent studies also implicated membrane lipid rafts in the
positive control of clustering and activation of integrins, in-
dicating that the role of the cytoskeleton may involve stabi-
lization of raft structures as well (61, 62). Combining our
data with these studies, we propose that upon BCR stimu-
lation  4 1 may initially be released from a cytoskeletal
constraint by Ca2 -mediated Calpain activation (CP-sensi-
tive) or actin depolymerization (JP-sensitive), followed by
Figure 5. BCR-controlled integrin  4 1-mediated adhesion involves
integrin clustering and cytoskeletal reorganization. (A) DT40 cells were
incubated without (open circles) or with 10  g/ml anti-IgM (closed
squares) or 3 mM MnCl2 (closed triangles) and 0, 2, or 10  g/ml soluble
VCAM-1-Fc, as indicated. Binding of soluble VCAM-1-Fc was measured by
FACS analysis. Mean fluorescence intensity (MFI) values of a representative
experiment are depicted. (B) DT40 cells, either WT or Btk-deficient
(Btk ), were not stimulated (C) or stimulated for 15 or 30 min with anti-IgM
(a-IgM) or PMA, as indicated. Clustering of integrin  4 1 was analyzed
by means of confocal microscopy. For each condition, representative images
of optical midheight sections (1st and 3rd row), and corresponding whole
cell projections along the z-axis using maximum fluorescence values (2nd
and 4th row), are shown. (C) Namalwa cells (left) or DT40 cells (right)
were pretreated for 30 min with 1  g/ml Cytochalasin D (CD), 1  M
Jasplakinolide (JP), 100  g/ml Calpeptin (CP), or left untreated, and
subsequently not stimulated (C) or stimulated with anti-IgM (a-IgM) and
plated on a surface coated with VCAM-1.T
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mobilization to lipid rafts which are stabilized by the cyto-
skeleton (JP- and CD-sensitive), and the subsequent forma-
tion of  4 1 clusters which may become tethered to the
(repolymerized) actin cytoskeleton again (JP- and CD-sen-
sitive), resulting in enhanced  4 1 avidity and adhesion.
Integrin  4 1-mediated Adhesion in B Cell Development and
Differentiation. During B cell development both the pre-
BCR (19, 21, 22), and integrin-mediated adhesion to
VCAM-1-expressing BM stromal cells and ECM (1, 3, 4),
play a critical role in the survival of preB cells and their dif-
ferentiation into immature B cells. The preBCR, which
presumably signals in a ligand-independent fashion, con-
trols signaling molecules similar to the BCR (42, 48).
Therefore, it is tempting to speculate that expression of the
preBCR controls integrin activity (see Fig. 3, D and E),
which may be required for retention of the preB cells in
the proper BM microenvironment and their transition into
immature B cells.
Previously, we and others have shown that the interaction
of GC B cells with FDCs, which plays a major role in anti-
gen-specific B cell differentiation, is mediated by  4 1 (2,
13, 14), and that adhesion through  4 1 suppresses apopto-
sis of GC B cells (16, 17). Combined with our present find-
ings, we propose that antigen-specific B cell differentiation is
controlled by stimulation of the BCR by the FDC-pre-
sented antigen, generating signals that result in inside-out in-
tegrin activation. This will “lock” the interaction of the GC
B cell with the FDC. The enhanced  4 1-mediated adhe-
sion to FDCs may counteract GC B cell migration along a
chemokine gradient, e.g., of BLC. After the initial migration
arrest, the integrin-mediated formation of clusters of B cells
and FDCs will give rise to the structural microenvironment
of the GC. The retention of the GC B cells in these GCs
and their contact with the FDC plays an important role in
affinity maturation: without the proper signals provided by
the GC microenvironment in general, and by the FDCs in
particular, GC B cells will not proliferate and undergo apop-
tosis (12, 15). Moreover, the interaction with the FDC also
generates integrin-mediated anti-apoptotic outside-in signals
which may directly contribute to the clonal selection of the
GC B cells (16, 17). Thus, by competing for antigen and in-
tegrin-mediated survival signals, B cells expressing a high af-
finity BCR will prevent or terminate the BCR signal in a B
cell of lower affinity, which will consequently “unlock”
from the FDC, resulting in apoptosis.
A Critical Role for Btk in the Control of Integrin Activity: Im-
plications for XLA and Xid. This study is the first to dem-
onstrate a critical role for Btk (and PLC 2 and IP3Rs) in
the control of integrin activity (Fig. 3). Interestingly, loss-
of-function germline mutations in the BTK gene give rise
to the B cell immunodeficiency disease XLA in humans
and Xid in mice. XLA patients show a severe reduction in
mature B cell numbers ( 99%) and consequently in Ig se-
rum levels (44, 45). In Xid and the phenotypically identical
Btk-deficient mice, however, mature B cell numbers are
only 50% reduced (63). This may be due to functional re-
dundancy of Btk with other Tec family members in murine
B cells, as illustrated by the ability to overcome signaling
defects in Btk-deficient DT40 cells and XLA patient B cells
by expression of other Tec family members (64, 65), and
the observation that, in contrast to the Btk- or Tec-defi-
cient mice, mature B-cells are almost absent in Btk/Tec
double-deficient mice (66). In particular since, in contrast
to Btk-deficient chicken DT40 cells (29) and XLA patient
B cells (65), Xid mice mature B cells also show (near) nor-
mal BCR-induced activation of PLC 2 (67), PI hydrolysis
(68), and Ca2  release (67–69), this species-specific redun-
dancy may explain why Btk-deficient murine naive B cells
exhibit normal BCR-induced adhesion as well (Fig. 3 C).
The earliest role for Btk in B cell development occurs at
the switch from preB cells to immature B cells, which is se-
verely impaired in XLA patients and, to a lesser extent, in
Xid and Btk /  mice (33, 43, 44). In XLA this is due to a
proliferation defect of the  H-chain positive preB cells
(45). Supported by the observation that the proliferation of
preB cells from  4 integrin-deficient mice is also reduced
(4), and because the preBCR signals through Btk (46, 48,
49), our results suggest that the loss of control of integrin-
mediated adhesion by the preBCR may contribute to this
Figure 6. Molecular dissection of the signaling cascade underlying
BCR-controlled integrin  4 1-mediated adhesion. A schematic repre-
sentation of the signaling pathway underlying the inside-out activation
mechanism of integrin  4 1 upon stimulation of the BCR is shown. The
proteins encoded for by the inactivated genes in the DT40 cells and the
pharmacological inhibitors used in this study are boxed and italicized,
respectively. For sake of clarity, the role of actin cytoskeleton (re)organi-
zation is not included. See the Discussion section for further detail.T
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proliferation defect in XLA preB cells (Fig. 3, D and E; see
also discussion above). In addition, both Btk and integrins
are involved in the retention (2, 70) and positive selection
(63, 71) of immature B cells in the BM, as well as in the
development, survival and follicular entry of long-lived re-
circulating follicular cells (33, 63, 72). Furthermore, besides
a loss of T-independent antigen responses, Xid and Btk-
deficient mice show a strongly reduced primary and a variably
affected secondary T-dependent antigen response, whereas
both responses are absent in Btk/Tec double-deficient,
which is accompanied by smaller follicles and less GCs (63,
66, 73, 74). Gain-of-function E41K-Btk transgenic mice
also revealed a loss of the T-dependent antigen response,
smaller follicles and the absence of marginal zones and GCs
(72). This may reflect a defect in (BCR-controlled)  4 1
activity of GC B cells, which, as discussed above, has an
important role in GC formation and antigen-specific B cell
differentiation. Finally, it is noteworthy that mice deficient
in the p85 subunit of PI3K, BLNK, PLC 2, or PKC ,
which like Btk play a critical role in the signaling cascade
underlying BCR-controlled integrin activity (Figs. 2, 4,
and 6), reveal a Xid-like phenotype as well (75).
In conclusion, whereas the control of integrin activity by
the (pre)BCR plays an important role in B cell develop-
ment and antigen-specific B cell differentiation, the loss of
control of integrin activity, due to loss-of-function germ-
line mutations of BTK, may contribute to the develop-
mental and functional B cell defects as observed in Xid
mice and XLA patients.
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